Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PAVmed Inc. - Series Z Warrant (NQ: PAVMZ )

0.0163 +0.0001 (+0.62%)
Streaming Delayed Price Updated: 11:38 AM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PAVmed Inc. - Series Z Warrant

< Previous 1 2 Next >
PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results
From PAVmed Inc. and Lucid Diagnostics Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021
From PAVmed Inc. and Lucid Diagnostics Inc.
Via Business Wire
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
From PAVmed Inc.
Via Business Wire
Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
From Lucid Diagnostics Inc.
Via Business Wire
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
From PAVmed Inc.
Via Business Wire
ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
From Lucid Diagnostics Inc.
Via Business Wire
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
From Lucid Diagnostics Inc.
Via Business Wire
How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More
Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward. What To Watch... 
Via Benzinga
Lucid Diagnostics Announces Pricing of Initial Public Offering
From PAVmed Inc.
Via Business Wire
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
From PAVmed Inc.
Via Business Wire
PAVmed to Host Digital Health Virtual Investor Event
From PAVmed Inc.
Via Business Wire
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
From PAVmed Inc.
Via Business Wire
PAVmed to Participate in September Investor and MedTech Conferences
From PAVmed Inc.
Via Business Wire
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
From PAVmed Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
From PAVmed Inc.
Via Business Wire
PAVmed to Present at the 41st Annual Canaccord Genuity Growth Conference
From PAVmed Inc.
Via Business Wire
Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
From PAVmed Inc.
Via Business Wire
CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
From PAVmed Inc.
Via Business Wire
PAVmed to Hold Business Update Conference Call on August 12, 2021
From PAVmed Inc.
Via Business Wire
Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors
From PAVmed Inc.
Via Business Wire
PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth
From PAVmed Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.